IN THE CLAIMS:

Claims 2-4, 14, 15, and 18 are canceled; claims 1, 5-13, and 16 are amended, and new claims 19-27 are added, as shown below:

-- 1. (Amended) A method of treating non-Hodgkin's lymphoma in a subject in need of such treatment comprising administering a therapeutically effective amount of:

(i) an anti-CD20 antibody having B-cell depleting activity, or a fragment thereof having B-cell depleting activity; and

a11

(ii) an anti-CD40L antibody that antagonizes interaction of CD40 and CD40L, or a fragment thereof that antagonizes interaction of CD40 and CD40L;

wherein said antibody administration is effected separately, in combination, and in either order of administration.

---

2. (canceled)

3. (canceled)

4. (canceled)

---

5. (Amended) The method of Claim 1 wherein the anti-CD20 antibody is a humanized, primatized, or chimeric anti-CD20 antibody.

a12

6. (Amended) The method of Claim 5 wherein the anti-CD20 antibody has at least 10% of the B cell-depleting activity of IDEC-C2B8.

7. (Amended) The method of claim 1 wherein the anti-CD40L antibody is a humanized, primatized, or chimeric anti-CD40L antibody.

8. (Amended) The method of claim 7 wherein the anti-CD40L antibody is humanized MAb 24-31.

9. (Amended) The method of Claim 1 wherein the anti-CD40L antibody is administered after the anti-CD20 antibody.

A12

10. (Amended) The method of Claim 1 wherein the anti-CD40L antibody is administered before the anti-CD20 antibody.

11. (Amended) The method of Claim 1 wherein the anti-CD20 antibody and the anti-CD40L antibody are administered within about a month of each other.

12. (Amended) The method of Claim 1 wherein the anti-CD20 antibody and the anti-CD40L antibody are administered within about one week of each other.

13. (Amended) The method of Claim 1 wherein the anti-CD20 antibody and the anti-CD40L antibody are administered within about 1 day of each other.

14. (canceled)

15. (canceled)

A 13

16. (Amended) The method of Claim 1 wherein at least one of the antibodies is attached to a radiolabel.

17. The method of Claim 1 which further comprises chemotherapy or radiation therapy.

18. (canceled)

The following new claims are added:

19. The method of Claim 5 wherein the anti-CD20 antibody is IDEC-C2B8.

20. The method of claim 1 wherein the anti-CD20 antibody is IDEC-C2B8 and the anti-CD40L antibody is humanized MAb 24-31.

A 14

21. The method of claim 1, wherein a weekly dose of said anti-CD20 antibody is 20 to 1000 mg/m^2, and a dose of said anti-CD40L antibody is 0.5 to 10 mg/kg body weight.

22. The method of claim 16 wherein the anti-CD20 antibody is radiolabeled with ^{90}Y.

23. The method of claim 22 wherein the radiolabeled anti-CD20 antibody is Y2B8.

24. A method of treating non-Hodgkin's lymphoma in a subject in need of such treatment comprising administering a therapeutically effective amount of:

(i) IDEC-C2B8, and

(ii) humanized MAb 24-31.

a14 wherein said antibody administration is effected separately, in combination, and in either order of administration.

25. The method of Claim 24, wherein the IDEC-C2B8 antibody and the humanized MAb 24-31 antibody are administered within about 1 day of each other.

26. The method of claim 24, wherein a weekly dose of IDEC-C2B8 is 20 to 1000 mg/m^2, and a dose of humanized MAb 24-31 antibody is 0.5 to 10 mg/kg body weight.

27. The method of claim 24, which further comprises chemotherapy or radiation therapy.

REMARKS

Submission of Corrected Drawings:

New Figures 2b and 4, corrected in accordance with the Notice of Draftspersons Patent Drawing Review dated March 11, 2002, are submitted with this reply as attachments to a separate transmittal letter addressed to the Official Draftsperson.

Amendment of the Specification:

The specification is amended to correct informalities (spelling and formatting errors) on pages 1, 14, 16-17, 40, 41, 46, and 47, as shown above. The specification was also amended on page 49 by insertion of text that descries A physical description of the